IceCure Medical (ICCM) Set to Announce Earnings on Wednesday

IceCure Medical (NASDAQ:ICCM) is set to announce its earnings results before the market opens on Wednesday, April 3rd. Analysts expect the company to announce earnings of ($0.08) per share for the quarter.

IceCure Medical Stock Up 0.8 %

Shares of NASDAQ ICCM opened at $1.19 on Thursday. IceCure Medical has a 1 year low of $0.52 and a 1 year high of $1.57. The firm’s 50-day moving average is $1.31 and its 200-day moving average is $1.06. The company has a current ratio of 4.03, a quick ratio of 3.41 and a debt-to-equity ratio of 0.03. The firm has a market capitalization of $54.29 million, a PE ratio of -3.22 and a beta of 0.75.

Analysts Set New Price Targets

ICCM has been the topic of a number of recent research reports. Alliance Global Partners raised their price objective on shares of IceCure Medical from $1.90 to $2.90 and gave the company a “buy” rating in a research note on Wednesday, March 20th. HC Wainwright restated a “buy” rating and issued a $3.00 price target on shares of IceCure Medical in a research report on Wednesday, March 20th.

Institutional Trading of IceCure Medical

Several hedge funds have recently added to or reduced their stakes in ICCM. UBS Group AG grew its stake in IceCure Medical by 1,302.3% in the fourth quarter. UBS Group AG now owns 28,986 shares of the company’s stock valued at $45,000 after acquiring an additional 26,919 shares during the period. Bank of America Corp DE lifted its holdings in shares of IceCure Medical by 57.2% during the 4th quarter. Bank of America Corp DE now owns 55,388 shares of the company’s stock valued at $86,000 after purchasing an additional 20,159 shares in the last quarter. Boothbay Fund Management LLC grew its position in shares of IceCure Medical by 100.0% in the 4th quarter. Boothbay Fund Management LLC now owns 40,000 shares of the company’s stock valued at $62,000 after purchasing an additional 20,000 shares during the period. Finally, JPMorgan Chase & Co. bought a new stake in IceCure Medical during the 2nd quarter worth approximately $78,000. Institutional investors and hedge funds own 0.62% of the company’s stock.

About IceCure Medical

IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and commercialization of medical devices for cryoablation (freezing) of tumors in the human body. It offers ProSense system, a single probe system for the treatment of breast tumors; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology.